Kaleo, Inc. ( Kaleo)

Primary tabs

Kaleo's picture

Management

Contact Address

About Kaleo, Inc.

Kaléo is a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions. Our mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions.

Kaleo press release, blog etc

Thu, 05/15/2025 - 07:29 Retrospective Analysis of U.S. Claims Data Shows AUVI-Q (epinephrine injection, USP) Prescription Associated with Lower Rates of Anaphylaxis-Related Inpatient Hospitalizations Compared to Other Epinephrine Auto-Injectors
Sun, 12/11/2022 - 22:39 Kaleo and Parexel Win Quality Award from the Abstract Committee of the American Conference on Pharmacometrics
Tue, 10/25/2022 - 14:36 Kaleo Announces Appointment of Major General Elder Granger, M.D., to Board
Tue, 09/27/2022 - 18:29 Kaleo Adds Chief Business Officer to Executive Team
Wed, 09/21/2022 - 12:52 Kaleo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
Tue, 09/13/2022 - 10:16 Rapid Opioid Countermeasure System Product Team Wins Award for Outstanding Program Management Team at 2022 Military Health System Research Symposium
Thu, 08/11/2022 - 13:08 Kaleo Announces Executive Appointments and New Government Business Unit
Tue, 03/01/2022 - 20:08 FDA Approves Kaleos Naloxone Auto-Injector 10 mg for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids
Mon, 11/29/2021 - 04:37 Marathon Asset Management Announces Acquisition of Kaleo
Mon, 08/10/2020 - 03:03 Kaleo and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT (epinephrine injection, USP) Auto-Injector for the Treatment of Serious Allergic Reactions Across Canadian Provinces
Tue, 05/12/2020 - 14:23 Kaleo Announces ALLERJECT (epinephrine injection, USP) Auto-Injector Will Be Available for Canadians at Risk for Anaphylaxis Starting
Tue, 05/12/2020 - 13:59 Kaleo annonce qua partir du 19 mai 2020 lauto-injecteur ALLERJECT (epinephrine injectable, USP) sera a la disposition des Canadiens a risque danaphylaxie.
Wed, 12/12/2018 - 15:50 Authorized Generic for EVZIO (naloxone HCl injection) to be Available at a Reduced List Price of $178
Wed, 08/29/2018 - 16:18 AUVI-Q (epinephrine injection, USP) Available in Canada Starting
Tue, 08/14/2018 - 16:20 Kaleo Confirms U.S. Availability of AUVI-Q (epinephrine injection, USP) Auto-injector for Back-to-School Season

InfoBox

HomePagewww.kaleopharma.com
Twittertwitter.com/kaleopharma
LinkedInwww.linkedin.com/company/kal%C3%A9o